Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Will Have Opportunity To Address Genomics In Review Of Glaxo/SB

Executive Summary

The Glaxo SmithKline merger will provide an opportunity for antitrust regulators to weigh in on the commercial exploitation of the human genome.

You may also be interested in...



Merck/Rosetta Scales Up Merck's Genomics Effort, Merger Comfort Level?

Merck's $620 mil. acquisition offer for Rosetta Inpharmatics will scale up Merck's genomics research efforts - and may also scale up its tolerance for mergers and acquisitions.

Merck/Rosetta Scales Up Merck's Genomics Effort, Merger Comfort Level?

Merck's $620 mil. acquisition offer for Rosetta Inpharmatics will scale up Merck's genomics research efforts - and may also scale up its tolerance for mergers and acquisitions.

Glaxo SmithKline EU Merger Approval Includes Potential Divestment Of Ariflo

Glaxo SmithKline will be required to divest the chronic obstructive pulmonary disease therapy Ariflo in Europe if all competing agents fail in clinical trials.

Related Content

UsernamePublicRestriction

Register

PS035476

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel